Stanford’s world class team of physicians, fellow and resident trainees, nurses, and research coordinators are actively involved in clinical research that helps improve the care of interstitial lung disease patients. Stanford’s ILD clinic has a robust clinical research program that offers a variety of types of protocols to patients with interstitial lung disease, including observational research, drug treatment clinical trials, and health sciences research that are described below.

The majority of our drug treatment trials are phase II and II and they are all outpatient studies of varying duration.  Our clinical trials are both industry and NIH funded.  When launching a new clinical trial, we typically review our own ILD database for qualified participants, but also recruit from the broader Bay Area and beyond.  Participants do not need to be Stanford patients.  Interested participants or their healthcare provider can email or call Susan Jacobs RN, MS, Research Nurse Manager 650 725 8083 to refer a patient for eligibility evaluation.

You can find out more about each trial or see if you might be a candidate by calling the Clinical Research Coordinator listed with each one.  You can also review these trials by reading about them on Clinicaltrials.gov; each trial has a National Clinical Trial (NCT) identifier which is also listed below.

Observational studies involve observing and collecting data on patients over time. These studies often involve a patient registry in which information on a patient’s symptoms, medications, medical test results, lab or tissue samples, and/or clinical course is collected and securely stored.

All patients with interstitial lung disease (ILD) evaluated at Stanford have the opportunity to participate in the Stanford ILD patient registry. Stanford ILD patients are asked to verbally provide informed consent; participation in the Stanford ILD registry is voluntary. Stanford’s team has used data from this registry to understand the natural history and prognosis of patients with ILD and to gain insights into interventions that may help improve the care of patients with ILD. The Stanford ILD patient registry has also been used to facilitate collaborative projects with colleagues from other divisions, such as rheumatology and radiology, and other institutions.

Stanford ILD Patient Registry
PI: Rishi Raj MD
CRC: Susan Jacobs 
Status: Enrollment is open to Stanford ILD clinic patients
NCT#: NA

Pulmonary Fibrosis Foundation Patient Registry
PI: Rishi Raj MD
CRC: Jannet Estrada, BA, CRCA
Status:  Enrollment is closed for this observational patient registry, but study is active
NCT#: 01915511

Idiopathic Pulmonary Fibrosis Prospective Outcomes Registry (IPF-PRO; ILD-PRO)
PI: Rishi Raj MD
CRC: Jannet Estrada, BA,CRCA
Status: Enrollment in this observational patient registry is currently closed to enrollment; previously enrolled participants with IPF are being followed.
NCT#: 01915511

Clinical trials are research studies that explore whether a medical treatment or intervention is safe and effective. Our ILD program has a variety of investigational treatment trials that are actively enrolling participants, including phase II and phase II studies.  To find out more about the interventional clinical trials listed here, please contact Stanford’s ILD research manager for more information.

1. A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects with Idiopathic Pulmonary Fibrosis (RIN-PF-301; TETON 301)
PI: Rishi Raj MD
CRC: Jeanette Smith
Status: Currently enrolling qualified patients with IPF; anti-fibrotic medications (Ofev or Esbriet) are allowed
Description: This is a one-year study that includes a study drug/placebo taken by nebulizer 4 times/day.

Eligibility Criteria:  find out more about this trial here including eligibility criteria.
NCT#: 04708782

2. A randomized, double-blind, dose-ranging, placebo-controlled study to evaluate the efficacy and safety of PLN-74809 (bexotegrast) for the treatment of idiopathic pulmonary fibrosis (BEACON)

PI: Joshua Mooney MD
CRC: Jannet Estrada, B.A.
Status: Currently enrolling qualifying patients with Idiopathic Pulmonary Fibrosis
Description: This is a one-year study that includes use of an oral (pill) anti fibrotic agent to slow the progression of IPF.

Eligibility Criteria: find out more about this trial here including eligibility criteria.
NCT#: 06097260

3. A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants with Idiopathic Pulmonary Fibrosis (ALOFT 068)
PI: Rishi Raj MD
CRC: Karima Belhocine
Status: Currently enrolling qualifying patients with IPF; current use of anti-fibrotic medications (Ofev or Esbriet) is allowed.
Description: This is a 12 month study that includes use an oral medication to slow fibrosis in the lung.

Eligibility Criteria: find out more about this trial here including eligibility criteria.
NCT#: 04072315

4. A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects with Progressive Pulmonary Fibrosis (TETON-PPF)(RIN PPF 305)
PI: Rishi Raj MD
CRC: Jannet Estrada B.A.
Status: Currently enrolling qualifying patients with Progressive Pulmonary Fibrosis; patients with Idiopathic Pulmonary Fibrosis are not eligible.

Description: This is a 12-month study that includes use of an oral medication to slow fibrosis.

Eligibility Criteria: find out more about this trial here including eligibility criteria.
NCT#: 05943535

5. A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants with Progressive Pulmonary Fibrosis (ALOFT 1015)
PI: Rishi Raj MD
CRC: Jannet Estrada B.A.
Status: Currently enrolling qualifying patients with non-IPF, progressive pulmonary fibrosis Description: this is a 12 month study of an oral drug with monthly study visits to Stanford.
Eligibility Criteria: find out more about this trial here including eligibility criteria.
NCT#: 04308681

1. Prospective Treatment Efficacy in IPF Using Genotype for Nac Selection (PRECISIONS) Trial (PRECISIONS)

PI: Joshua Mooney MD
CRC: Jeanette Morris BA 650 736 8083
Status: Currently enrolling qualifying patients with IPF; current use of anti-fibrotic medications (Ofev or Esbriet) is allowed.
Eligibility Criteria: find out more about this trial including eligibility criteria.
NCT#: 04300920

Health services research involves studying how patients access health care, and understanding the costs and outcomes associated with their health care. At Stanford, our physician scientists have used Centers for Medicare and Medicaid Services (CMS) data, the National Inpatient Sample (NIS) data, and other large databases to study health care access, healthcare disparities, healthcare outcomes, and economic costs in interstitial lung disease. For example, Stanford’s team has evaluated the patterns of health care testing prior to ILD diagnosis in Medicare patients to understand potential delays to diagnosis and have evaluated hospitalized patients with ILD who receive mechanical ventilation to understand their outcomes. Collaborative work with colleagues from Stanford’s Center for Health Policy, Center for Primary Care and Outcomes Research, and Center for Population Health Sciences helps enable projects like these.